

INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)	Attorney Docket No. 056291-5303	Application No. 10/594,233
	Applicants: Stephen WEDGE et al.	
	Filing Date: September 25, 2006	Group Art Unit: 4161

PTO Form 1449
October 14, 2008

U.S. PATENT DOCUMENTS

Initial		Document No.	Date	Name	Class	Sub-Class	Filing Date
1.		US 20030144298	July 31, 2003	Curwen et al.			
2.		US 20060142316	June 29, 2006	Wedge et al.			
3.		US 20060160775	July 20, 2006	Wedge			
4.		US 20060167024	July 27, 2006	Wedge			
5.		US 20070135462	June 14, 2007	Wedge			
6.		US 20080015205	January 17, 2008	Wedge			
7.		US 20080113039	May 15, 2008	Wedge			

FOREIGN PATENT DOCUMENTS

		Document No.	Date	Country	Class	Sub-Class	Translation
8.		WO 00/47212	August 17, 2000	WIPO			
9.		WO 01/74360	October 11, 2001	WIPO			
10.		WO 2004/071397	August 26, 2004	WIPO			
11.		WO 2005/004871	January 20, 2005	WIPO			
12.		WO 2005/004872	January 20, 2005	WIPO			
13.		WO 2005/061488	July 7, 2005	WIPO			
14.		WO 2005/092384	October 6, 2005	WIPO			
15.		WO 2005/092385	October 6, 2005	WIPO			
16.		WO 2006/035203	April 6, 2006	WIPO			
17.		WO 2007/003933	January 11, 2007	WIPO			
18.		WO 2007/071970	June 28, 2007	WIPO			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, etc.)

19. Ferrari et al. "Three drugs schedule in metastatic colorectal cancer (MCC). A phase II study of sequential irinotecan (CPT11), oxaliplatin (L-OHP) plus folinic acid (FA) and short fluorouracil (5FU) infusion" European Journal of Cancer. Supplement, 1(5): S76 (2003)

20. Malik et al. "Targeting VEGF ligands and receptors in cancer" Targets, 2(2):48-57 (2003)

21. Marmer "The impact of anti-angiogenic agents on cancer therapy" Journal of Cancer Research and Clinical Oncology 129(11): 607-620 (2003)

22. Wheeler et al. "Novel approaches in oncology at AstraZeneca" European Journal of Cancer. Supplement, 1(8):3-8 (2003)

Examiner

Date Considered

Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.